Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;19(7 Suppl 3):9-10.

The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

No authors listed

The Efficacy and Safety of Guselkumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

No authors listed. Gastroenterol Hepatol (N Y). 2023 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 6.
Figure 6.
Comparison of the proportions of patients in clinical remission at week 12 treated with guselkumab or placebo. Adapted from Allegretti et al. Abstract 913b. Presented at: DDW 2023; May 6-9, 2023; Chicago, Illinois.

References

    1. Hanzel J, Hulshoff MS, Grootjans J, D’Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol. 2022;18(5):513–524. - PubMed
    1. Allegretti JR, Peyrin-Biroulet L, Feagan BG The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 Quasar induction study. Abstract 913b. 2023. Presented at: DDW 2023; May 6-9. Chicago, Illinois. - PMC - PubMed
    1. First phase 3 TREMFYA® (guselkumab) data in inflammatory bowel disease show positive induction results among patients with moderately to severely active ulcerative colitis [press release]. Spring House, Pennsylvania. Johnson & Johnson. May 9, 2023.

LinkOut - more resources